Schonfeld Strategic Advisors LLC Grows Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Schonfeld Strategic Advisors LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,963 shares of the medical research company’s stock after buying an additional 152 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Charles River Laboratories International were worth $732,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in CRL. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new stake in Charles River Laboratories International in the 4th quarter worth approximately $37,000. GeoWealth Management LLC grew its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $48,000. Finally, Tortoise Investment Management LLC lifted its holdings in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after acquiring an additional 115 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on CRL. UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Barclays lifted their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus price target of $176.00.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 1.8 %

NYSE:CRL opened at $138.84 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a market capitalization of $6.82 billion, a PE ratio of 925.60, a P/E/G ratio of 4.54 and a beta of 1.50. The firm’s 50-day moving average price is $138.40 and its 200-day moving average price is $166.46. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter last year, the firm earned $2.27 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).